A Study of Pertuzumab in Participants With Prostate Cancer

Phase 2TerminatedNCT02480010

Hoffmann-La Roche68 enrolled

Overview

This study will evaluate the efficacy and safety of intravenous (IV) pertuzumab in participants with hormone-refractory prostate cancer who have had no previous chemotherapy. Participants will be enrolled in two stages, the first (Cohort A) at a lower 420-mg dose and the second (Cohort B) at a higher 1050-mg dose based upon observations in Cohort A. Up to 50 participants may enter either cohort, for a total enrollment between 46 and 73 participants across 9 study centers.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Prostate Cancer

Interventions

PertuzumabDRUG

Participants will receive pertuzumab on Day 1 of each 3-week cycle. In Cohort A, an 840-mg loading dose will be administered prior to the 420-mg IV infusion. In Cohort B, the 1050-mg IV infusion will be administered with no loading dose.

Eligibility

Sex: MALEMin age: 19 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adults greater than (\>) 18 years of age * Histologically documented adenocarcinoma of the prostate resistant to hormone therapy, progressed at 4 to 6 weeks following anti-androgen withdrawal * Prostate-specific antigen (PSA) values at least 20 ng/mL among those with asymptomatic or mildly symptomatic disease * Karnofsky performance status (KPS) at least 80 percent (%) * Castrate testosterone less than (\<) 50 ng/dL * Life expectancy at least 12 weeks * Left ventricular ejection fraction (LVEF) at least 50% * Adequate hematologic, hepatic, and renal function Exclusion Criteria: * Prior chemotherapy, radionucleotide therapy, or immunotherapy for prostate cancer * Systemic corticosteroids within 1 month prior to Screening * Bisphosphonates within 6 months, narcotic analgesics within 2 weeks, or any investigational agent with 28 days of study drug * Prior cumulative doxorubicin dose of \> 360 mg/m\^2 or equivalent * Central nervous system (CNS) or pulmonary metastases * Other malignancies, except adequately treated basal or squamous cell skin cancer * Significant cardiovascular disease * Active/uncontrolled concurrent illness or infection * Major surgery or traumatic injury within 4 weeks of study drug

Locations (11)

Unnamed facility

Lyon, France

Unnamed facility

Montpellier, France

Unnamed facility

Berlin, Germany

Unnamed facility

Parma, Italy

Outcomes

Primary Outcomes

Percentage of Participants With Confirmed, Objective Response, Non-Response or Progressive Disease by PSA Levels Within the First 24 Weeks of Treatment With Pertuzumab

Objective PSA response rate was determined according to Prostate Specific Antigen Working Group (PSAWG) guidelines. All participants achieving a drop in PSA of greater than or equal to (≥) 50 percent (%) from baseline (confirmed with a second value at least 4 weeks later) fulfilled the criteria of a PSA response. The confirmatory second value had to be at least 50% lower than baseline, but could be higher than the first drop in PSA. Confirmatory value could not be 50% higher compared to first drop in PSA. The date of response was the date the first 50% (or greater) decline was observed. Progressive disease (PD) was defined by a minimum of three consecutive serum PSA measurements obtained at least 7 days apart within the previous 3 months of start of trial, which documented progressively increasing values. Non-response was defined as neither PD nor Response.

Time frame: Screening, Every 3 weeks up to Week 24

Secondary Outcomes

Time to Disease Progression

Time to disease progression was defined by time in weeks from start of therapy to the onset of the earliest of the following events. 1) PSA progression as defined by the PSAWG, 2) Evidence of disease progression according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria 3) One bone scan at least 6 months subsequent to baseline demonstrating 2 or more new skeletal lesions and 4) An event due to metastatic prostate cancer requiring intervention.

Time frame: Screening, Every 3 weeks up to a maximum of 18 months

Percentage of Participants With Objective Response (Complete Response [CR] or Partial Response [PR]) by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria

Overall objective response by RECIST criteria (CR or PR) was to be defined for participants who had measurable disease at baseline or developed new lesions post-baseline. The longest diameter only for all target lesions was measured and the following responses recorded: CR: disappearance of all target lesions. PR: at least a 30% decrease in the sum of the longest diameter as compared to the baseline sum longest diameter.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Unnamed facility

Roma, Italy

Unnamed facility

Rotterdam, Netherlands

Unnamed facility

Barcelona, Spain

Unnamed facility

Valencia, Spain

Unnamed facility

Cardiff, United Kingdom

Unnamed facility

Sutton, United Kingdom

...and 1 more locations

Time frame: Screening, Weeks 6, 12, 24, 36 and 48

Time to Response

Time to response was the date of the first documentation of PSA response.

Time frame: Screening, Every 3 weeks for a maximum of 18 months

Duration of Response According to PSA Levels

Duration of PSA Response was measured from first 50% decline in PSA compared to baseline until the time at which there was an increase of ≥50% from the PSA nadir, provided the absolute increase was at least 5 nanograms per milliliter (ng/ml). The increase must have been confirmed by a second consecutive measurement that was at least 50% above the nadir.

Time frame: Baseline, Every 3 weeks for a maximum of 18 months

Duration of Response According to RECIST Criteria

For participants with measurable disease, duration of response was defined as first documentation of tumor response, either a PR or CR, to first documentation of PD or death. Participants who never progressed or died were censored at their last tumor measurement.

Time frame: Baseline, Weeks 6, 12, 24, 36 and 48

Percentage of Participants Without Progression

Disease progression was defined as the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. Non-progression included participants who had responded plus those who had not responded and not progressed within the first 3 cycles.

Time frame: Screening, Weeks 3, 6, 9 and 12

Time to Prostate Cancer Pain Progression

Time to disease progression was defined by time in weeks from start of therapy to the onset of the earliest of the following events: 1) Opioid therapy, 2) Radiation therapy, 3) Glucocorticoid therapy, 4) Radionuclide therapy or 5) Chemotherapy.

Time frame: Every 3 weeks up to a maximum of 18 weeks

Overall Survival

Overall survival was defined as the interval of time in weeks between start of treatment and day of death. Participants who did not die while being followed were censored at the last time that they were known to be alive.

Time frame: Screening, Every 3 weeks up to a maximum of 18 months

Time to Treatment Failure

Time to Treatment Failure was time to the first documentation of progressive disease, day of death while on study (or 30 days after withdrawing from the trial) or day of early discontinuation due to toxicity (adverse events or abnormal laboratory value), refusal of treatment/refusing to cooperate/withdrawing consent, insufficient therapeutic response, or failure to return, whichever is earliest, after the start of treatment. Participants who did not experience any of the above events while on study were censored on the day of their last PSA or tumor measurement, whichever was later.

Time frame: Every 3 weeks up to a maximum of 18 weeks

Change From Baseline in Bone Alkaline Phosphatase

Bone alkaline phosphatase (BAP) is the bone-specific isoform of alkaline phosphatase. Serum Bone alkaline phosphatase is used to measure osteoporosis and is measured as units per liter (u/L).

Time frame: Screening, Weeks 6, 12, 24, 36 and 48

Change From Baseline in N-Telopeptide

In bone physiology, the N-terminal telopeptide (or more formally, amino-terminal collagen crosslinks, and known by the acronym NTX) is a telopeptide that can be used as a biomarker to measure the rate of bone turnover. NTX can be measured in the urine (uNTX) or serum (serum NTX).

Time frame: Screening, Weeks 6, 12, 24, 36 and 48

Area Under the Concentration Curve Extrapolated to Infinity (AUC0-Inf) of Pertuzumab

The area under the plot of plasma concentration of drug against time after drug administration is defined as the area under the curve (AUC). The AUC0-infinity is calculated from time 0 (prior to administration of medication) to infinity (the time of complete elimination of the drug). The AUC is of particular use in estimating the bioavailability of drugs, by measuring the extent of absorption. AUC is measured as micrograms times days per milliliter (µg\*day/mL)

Time frame: Cycles 1 and 2 (Weeks 3 and 6): predose (immediately prior to infusion) and within 15 minutes following the end of the infusion on Day 1, Day 8, and Day 15. Cycle 3 (Week 9) and beyond: predose and within 15 minutes following end of infusion on Day 1

AUC to Last Measurable Concentration (AUC0-last) of Pertuzumab

The AUC0-last is calculated from time 0 (prior to administration of medication) to last measured data point. The AUC is of particular use in estimating the bioavailability of drugs, by measuring the extent of absorption.

Maximum Plasma Concentration of Pertuzumab

Cmax is the maximum (or peak) plasma concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administered and prior to the administration of a second dose. Cmax is measured as micrograms per mL (μg/mL).

Time to Maximum Plasma Concentration (Tmax) of Pertuzumab

Cmax refers to the maximum (or peak) plasma concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administered and prior to the administration of a second dose. tmax is the time at which the Cmax is observed.

Time frame: Cycles 1 and 2 (Weeks 3 and 6): predose (immediately prior to infusion) and within 15 minutes following the end of the infusion on Day 1 and on Days 8 and 15, Cycle 3 (Week 9) and beyond: predose and within 15 minutes following end of infusion on Day 1

Terminal Elimination Half-Life (t1/2) of Pertuzumab

t1/2 is the time in days required for the concentration of the drug to reach half of its original value

Serum Clearance of Pertuzumab

Clearance (expressed as volume/time) describes the removal of drug from a volume of plasma in a given unit of time (drug loss from the body). It is measured as milliliters per day (mL/day).

Volume of Distribution at Steady State of Pertuzumab

The volume of distribution at steady state (Vss), also known as apparent volume of distribution, is a pharmacological, theoretical volume that the total amount of administered drug would have to occupy (if it were uniformly distributed), to provide the same concentration as it currently is in blood plasma.

Mean Residence Time (MRT) of Pertuzumab

MRT is the average time that pertuzumab is present in the systemic circulation and is measured in days.